Analysis Links Imaging Features, Genetic Variant to nAMD Conversion


Investigators examined more than 600 fellow eyes in a secondary analysis to identify 2 imaging features and 1 genetic variant linked to conversion.

neovascular age-related macular degeneration, nAMD, imaging, genetic variants

A recent secondary analysis has identified 2 imaging features and 1 genetic variant that were associated with conversion to neovascular age-related macular degeneration (nAMD).

Investigators found that genetic variant rs61941274, mean drusen reflectivity, and total en face area of drusen restricted to a circular area 3mm from the fovea were associated with conversion to nAMD.

Investigators carried out a retrospective, post hoc secondary analysis of the Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (HARBOR) randomized trial. The HARBOR trial was a 2-year phase 3 multicenter, prospective, randomized, double-masked, active treatment-controlled clinical trial focused on safety and efficacy of intraviteral ranibizumab on a monthly or pro re nata treatment regimen for patients with choroidal neovascularization secondary to wet AMD. A total of 686 fellow eyes were included in the investigator’s analysis and all eyes had nonneovascular AMD at baseline.

Investigators extracted imaging features describing the presence, number, extent, density, and relative reflectivity of druse from spectral-domain optical coherence tomography scans. Genetic analysis included 34 single-nucleotide polymorphisms. Investigators performed survival analysis and Cox proportional hazards regression to determine the association of the selected imaging features and genetic and demographic factors with conversion to neovascular AMD (nAMD).

Investigators noted that treatment in 1 eye was not associated with conversion to nAMD in the fellow eye. A bivariate analysis showed older patients (mean age of 79.5 years) and women(68.8% versus 56.4%) were more likely to experience conversion to nAMD. Among the 34 genetic variants, rs61941274 was significantly associated with conversion to nAM (95.5% versus 89.1%).

After an automated LASSO regression, investigators found that a druse area within 3mm of the fovea (HR, 1.45; 95% CI, 1.24-1.69; HR for 1-SD increase, 1.36 [95% CI, 1.20-1.54]) and mean drusen reflectivity (HR, 3.97; 95% CI, 1.11-14.18; HR for 1-SD increase, 1.32 [95% CI, 1.02-1.71]) were significantly associated with conversion to nAMD.

Authors noted several limitations within their study. The data for eyes analyzed for progression of AMD from a controlled clinical trial setting might differ between centers and their results may not be applicable to a real-world clinical population. Additionally, the limited sample size could have contributed to the lack of significant results for apparent demographic and risk factors previously shown to be associated with progression to nAMD. The feature-extraction algorithm targets areas where druse is present so some hyper-reflectivity may not have been identified if it was not overlying a drusen.

In an invited commentary, Maureen Maguire, PhD, professor of ophthalmology at the Perlman School of Medicine, University of Pennsylvania, wrote that demonstrated advances in imaging mean that technology will likely find its way into patient care, but long-term studies are needed to understand the earliest initiating events and create better prevention strategies.

“(Imaging and automated analysis) will likely replace time-consuming manual grading for research studies and make their way into patient care,” Maguire wrote. “However, the accuracy of these predictive models does not appear to be better than for previous predictive models based on manual grading, and additional features associated with disease progression have not yet been identified.”

This study, titled “Imaging, Genetic, and Demographic Factors Associated With Conversion to Neovascular Age-Related Macular Degeneration,” was published in JAMA Ophthalmology.

Related Videos
Peter A. Campochiaro, MD: RGX-314 for nAMD | Image Credit: Johns Hopkins Medicine
© 2024 MJH Life Sciences

All rights reserved.